Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | IO102-IO103 + Pembrolizumab |
Indication/Tumor Type | head and neck squamous cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | head and neck squamous cell carcinoma | predicted - sensitive | IO102-IO103 + Pembrolizumab | Case Reports/Case Series | Actionable | In a Phase II trial, treatment with the combination of IO102-IO103 and Keytruda (pembrolizumab) demonstrated safety and resulted in a partial response in 50% (2/4, 1 confirmed partial response) in patients with squamous cell carcinoma of the head and neck with CD274 (PD-L1) expression (combined positive scores >/=20) (Ann Oncol (2023) 34 (suppl_2): S630; NCT05077709). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
1038P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN) | Full reference... |